Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Savient Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Richard Crowley, Co-President and Chief Operating Officer, Philip K. Yachmetz, Co-President and Chief Business Officer, and John P. Hamill, Co-President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
SAVIENT PHARMACEUTICALS , INC. (Registrant) | ||
| By: | /s/ Richard Crowley | |
| Richard Crowley | ||
Co-President and Chief Operating Officer (Principal Executive Officer) | ||
| By: | /s/ Philip K. Yachmetz Philip K. Yachmetz | |
Co-President and Chief Business Officer (Principal Executive Officer) | ||
| By: | /s/ John P. Hamill | |
| John P. Hamill | ||
| Co-President and Chief Financial Officer | ||
| (Principal Financial Officer) | ||
August 14, 2013
